Fig. 1: Effect of empagliflozin versus placebo on time-to-first-event outcomes and total heart failure hospitalizations by LVEF category.

Hazard ratios for the primary endpoint, first hospitalization for heart failure (HHF), cardiovascular (CV) death and all-cause mortality were calculated using a multivariable Cox regression model, whereas the hazard ratio for total HHF was calculated using a joint frailty model with CV death as competing risk, as described in the Methods. Data are presented as point estimates and 95% CIs with two-sided P values. No adjustments for multiple testing were made.